PDF(Pubmed)
Abstract：
Antimicrobial resistance is a global public health threat, and the World Health Organization (WHO) has announced a priority list of the most threatening pathogens against which novel antibiotics need to be developed. The discovery and introduction of novel antibiotics are time-consuming and expensive. According to WHO\'s report of antibacterial agents in clinical development, only 18 novel antibiotics have been approved since 2014. Therefore, novel antibiotics are critically needed. Artificial intelligence (AI) has been rapidly applied to drug development since its recent technical breakthrough and has dramatically improved the efficiency of the discovery of novel antibiotics. Here, we first summarized recently marketed novel antibiotics, and antibiotic candidates in clinical development. In addition, we systematically reviewed the involvement of AI in antibacterial drug development and utilization, including small molecules, antimicrobial peptides, phage therapy, essential oils, as well as resistance mechanism prediction, and antibiotic stewardship.
摘要：
抗菌素耐药性是全球公共卫生威胁，世界卫生组织（WHO）已经宣布了一份需要开发新型抗生素的最具威胁性的病原体的优先清单。新型抗生素的发现和引入耗时且昂贵。根据世界卫生组织关于抗菌药物临床发展的报告,自2014年以来，只有18种新型抗生素获得批准。因此,急需新型抗生素。自最近的技术突破以来，人工智能（AI）已迅速应用于药物开发，并大大提高了发现新型抗生素的效率。这里,我们首先总结了最近上市的新型抗生素，和临床开发中的抗生素候选物。此外,我们系统地综述了人工智能在抗菌药物开发和利用中的作用，包括小分子，抗菌肽，噬菌体疗法,精油，以及抗性机制预测，和抗生素管理。
